Center for iPS Cell Research Application (CiRA) of Kyoto University and Takeda Pharmaceutical Company Limited (Takeda) announced today that they will work together to develop clinical applications of ...

A group of researchers in Japan says it has confirmed a certain level of efficacy in using iPS cell-derived immune cells for ...

TOKYO & PALO ALTO, Calif.--(BUSINESS WIRE)--Heartseed Inc. ("Heartseed"), a Tokyo-based biotechnology company developing iPSC-derived cardiomyocytes for heart failure and I Peace Inc. ("I Peace"), a ...

I Peace will provide its GMP iPS cell-related technology to generate the MCB's for the parent line and the modified subclones, while Vita will provide the technology necessary for gene editing and ...

Japanese researchers have made progress in the treatment of spinal cord injuries, offering hope to the approximately 20 million people worldwide affected by paralysis. On March 21, scientists from ...

TOKYO & MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--BrightPath Bio (Tokyo Stock Exchange Growth 4594, “BrightPath”), a pioneer in iPS cell-derived Natural Killer T (“NKT”) cell therapy, and ...

Three lines of GMP iPS Cells derived from type O female blood are now offered as off-the-shelf product It is well known that HLA homozygous iPSCs are often selected to reduce adverse immune response ...